Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
